

## Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the application.

### Listing of claims:

1. (Currently amended) A process for producing a block copolymer-drug composite, comprising the steps of dissolving an AB type block copolymer composed of hydrophilic polymer structure moiety and hydrophobic polyamino acid structure moiety together with a drug in a mixed solvent of water and ~~a low-boiling point organic solvent miscible with water~~ methanol, ethanol, isopropanol or acetone, and concentrating the resultant solution, wherein neither a dialysis nor an ultrafiltration process is included in the production process.

2. (Cancelled)

3. (Previously presented) The process for producing a block copolymer-drug composite according to claim 1, wherein the hydrophilic polymer structure moiety in the AB type block copolymer is a polyethylene oxide derivative, and the hydrophobic polyamino acid structure moiety in the AB type block copolymer is polyaspartic acid containing aspartic acid having a side chain carboxyl group bonded by an anthracycline-based

anticancer agent.

4. (Previously presented) The process for producing a block copolymer-drug composite according to claim 1, wherein the hydrophilic polymer structure moiety in the AB type block copolymer is a polyethylene oxide derivative, and the hydrophobic polyamino acid structure moiety in the AB type block copolymer is polyglutamic acid containing glutamic acid having a side chain carboxyl group bonded by an anthracycline-based anticancer agent.

5. (Original) The process for producing a block copolymer-drug composite according to claim 3 or 4, wherein the anthracycline-based anticancer agent bonded to a side chain carboxyl group on the hydrophobic polyamino acid structure moiety is doxorubicin.

6. (Previously presented) The process for producing a block copolymer-drug composite according to any one of claims 1, 3 or 4, wherein the drug is an anthracycline-based anticancer agent.

7. (Original) The process for producing a block copolymer-drug composite according to claim 6, wherein the anthracycline-based anticancer agent is doxorubicin or a salt thereof.

8. (Currently amended) A process for producing a lyophilization preparation containing a block copolymer-drug composite, comprising the steps of dissolving an AB type block copolymer

composed of hydrophilic polymer structure moiety and hydrophobic polyamino acid structure moiety together with a drug in a mixed solvent of water and ~~a low-boiling-point organic solvent miscible with water~~ methanol, ethanol, isopropanol or acetone, concentrating the resultant solution, and further lyophilizing this, wherein neither a dialysis nor an ultrafiltration process is included in the production process.